5-Bromo-2-Chlorobenzoic Acid CAS 21739-92-4 ʻOihana Kūwaena ʻo Dapagliflozin

ʻO ka wehewehe pōkole:

Inoa Kemika: 5-Bromo-2-Chlorobenzoic Acid

CAS: 21739-92-4

ʻIke: ≥99.0%

ʻAno: Keʻokeʻo-keʻokeʻo a i ka pauda Melemele Māmā

ʻO ka waena o Dapagliflozin (CAS: 461432-26-8) i ka mālama ʻana i ka maʻi diabetes type II

ʻO ke kūlana kiʻekiʻe, ka hana kālepa

Inquiry: alvin@ruifuchem.com


Huahana Huahana

Nā Huahana Pili

Huahana Huahana

wehewehe:

Mea Manufacturer Supply, High Purity, Commercial Production
Dapagliflozin (CAS: 461432-26-8) Nā Kūwaena Pili:
5-Bromo-2-Chlorobenzoic Acid CAS 21739-92-4
5-Bromo-2-Chloro-4'-Ethoxydiphenylmethane CAS 461432-23-5
2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone CAS 32384-65-9

Na Waiwai Kemika:

Inoa Kimia 5-Bromo-2-Chlorobenzoic Acid
Nā huaʻōlelo like 2-Chloro-5-Bromobenzoic Acid
Helu CAS 21739-92-4
Helu CAT RF-PI439
Kūlana Kūʻai Ma ka waihona, ʻoi aku ka nui o ka hana a hiki i nā tona
ʻĀpana Molekala C7H4BrClO2
Kaumaha Molecular 235.46
Lae hehee 154.0 a i 156.0 ℃ (māmā)
Brand ʻO Ruifu Chemical

Nā kikoʻī:

'ikamu Nā kikoʻī
Ka nana aku Pau-keʻokeʻo a i ka pauda Melemele Māmā
Hoʻāʻo ≥99.0%
Wai (KF) ≤0.50%
Koena ma ka Ignition ≤0.30%
2-Chlorobenzoic Acid ≤0.30%
2-Chloro-3-Bromobenzoic Acid ≤0.30%
Huina paumaele ≤1.0%
Kūlana hoʻāʻo ʻOihana Kūlana
Hoʻohana Ka waena o Dapagliflozin (CAS: 461432-26-8), ʻano maʻi diabetes II

Pūʻolo a me ka waiho ʻana:

Pūʻolo: ʻO ka ʻōmole, ʻeke ʻeke alumini, 25kg / pahu pahu pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.

Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;E pale i ka malamalama a me ka wai.

Pono:

1

FAQ:

Noi:

Hoʻohana ʻia ka 5-Bromo-2-Chlorobenzoic Acid (CAS: 21739-92-4) ma ke ʻano he mea hoʻomaka i ka synthesis o Dapagliflozin (CAS: 461432-26-8), kahi mea koho sodium-glucose cotransporter-2 inhibitor e hōʻemi i ka renal. glucose reabsorption a hoʻohana ʻia e mālama i nā maʻi me ka maʻi diabetes type II.ʻO Dapagliflozin kahi mea pale SGLT-2 (SLC5A2) ikaika a koho me EC50 o 1.1 nM.Loaʻa iā ia ka permeability maikaʻi ma waena o nā membrane cell Caco-2 a he substrate no ka P-glycoprotein (P-gp).Ua ʻae ʻia ʻo Dapagliflozin i ka makahiki 2012 e FDA.

E kākau i kāu leka ma aneʻi a hoʻouna mai iā mākou